These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30924452)

  • 1. Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms.
    Huang YH; Zhang YQ; Huang JT
    Asian J Androl; 2019; 21(3):291-295. PubMed ID: 30924452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
    Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PC3 is a cell line characteristic of prostatic small cell carcinoma.
    Tai S; Sun Y; Squires JM; Zhang H; Oh WK; Liang CZ; Huang J
    Prostate; 2011 Nov; 71(15):1668-79. PubMed ID: 21432867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate.
    Heaphy CM; Haffner MC; Graham MK; Lim D; Davis C; Corey E; Epstein JI; Eisenberger MA; Wang H; De Marzo AM; Meeker AK; Lotan TL
    Hum Pathol; 2020 Jul; 101():70-79. PubMed ID: 32389660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.
    Chen H; Sun Y; Wu C; Magyar CE; Li X; Cheng L; Yao JL; Shen S; Osunkoya AO; Liang C; Huang J
    Endocr Relat Cancer; 2012 Jun; 19(3):321-31. PubMed ID: 22389383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine cells of the prostate: Histology, biological functions, and molecular mechanisms.
    Butler W; Huang J
    Precis Clin Med; 2021 Mar; 4(1):25-34. PubMed ID: 33842835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer.
    Butler W; Xu L; Zhou Y; Cheng Q; Hauck JS; He Y; Marek R; Hartman Z; Cheng L; Yang Q; Wang ME; Chen M; Zhang H; Armstrong AJ; Huang J
    J Pathol; 2023 May; 260(1):43-55. PubMed ID: 36752189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma.
    Li Z; Sun Y; Chen X; Squires J; Nowroozizadeh B; Liang C; Huang J
    Mol Cancer Res; 2015 Mar; 13(3):584-91. PubMed ID: 25512615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: Histological features for accurate diagnosis and toward future novel therapies.
    Ida A; Okubo Y; Kasajima R; Washimi K; Sato S; Yoshioka E; Osaka K; Suzuki T; Yamamoto Y; Yokose T; Kishida T; Miyagi Y
    Pathol Res Pract; 2022 Jan; 229():153731. PubMed ID: 34952423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation.
    Lipianskaya J; Cohen A; Chen CJ; Hsia E; Squires J; Li Z; Zhang Y; Li W; Chen X; Xu H; Huang J
    Asian J Androl; 2014; 16(4):541-4. PubMed ID: 24589459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
    Beltran H; Rickman DS; Park K; Chae SS; Sboner A; MacDonald TY; Wang Y; Sheikh KL; Terry S; Tagawa ST; Dhir R; Nelson JB; de la Taille A; Allory Y; Gerstein MB; Perner S; Pienta KJ; Chinnaiyan AM; Wang Y; Collins CC; Gleave ME; Demichelis F; Nanus DM; Rubin MA
    Cancer Discov; 2011 Nov; 1(6):487-95. PubMed ID: 22389870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells.
    Ciarlo M; Benelli R; Barbieri O; Minghelli S; Barboro P; Balbi C; Ferrari N
    Int J Cancer; 2012 Aug; 131(3):582-90. PubMed ID: 22015967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GABA promotes gastrin-releasing peptide secretion in NE/NE-like cells: Contribution to prostate cancer progression.
    Solorzano SR; Imaz-Rosshandler I; Camacho-Arroyo I; García-Tobilla P; Morales-Montor G; Salazar P; Arena-Ortiz ML; Rodríguez-Dorantes M
    Sci Rep; 2018 Jul; 8(1):10272. PubMed ID: 29980692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of neuroendocrine cells in prostate cancer progression].
    Sciarra A; Innocenzi M; Ravaziol M; Minisola F; Alfarone A; Cattarino S; Panebianco V; Buonocore V; Gentile V; Di Silverio F
    Urologia; 2011; 78(2):126-31. PubMed ID: 21574145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular model for neuroendocrine prostate cancer progression.
    Chen R; Dong X; Gleave M
    BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.
    Moritz T; Venz S; Junker H; Kreuz S; Walther R; Zimmermann U
    Tumour Biol; 2016 Aug; 37(8):10435-46. PubMed ID: 26846108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
    Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
    Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuroendocrine differentiation in prostate cancer].
    Wu CY; Na YQ; Yao JL; di Sant'Agnese PA; Huang JT
    Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):565-7. PubMed ID: 17134555
    [No Abstract]   [Full Text] [Related]  

  • 19. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
    Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
    J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma.
    Sagnak L; Topaloglu H; Ozok U; Ersoy H
    Clin Genitourin Cancer; 2011 Dec; 9(2):73-80. PubMed ID: 22035833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.